Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(1.62) by 5.56 percent. This is a 13.33 percent decrease over losses of $(1.35) per share from the same period last year. The company reported quarterly sales of $34.11 million which beat the analyst consensus estimate of $29.24 million by 16.65 percent. This is a 33.82 percent decrease over sales of $51.53 million the same period last year.
Blueprint Medicines Q4 EPS $(1.53) Beats $(1.62) Estimate, Sales $34.11M Beat $29.24M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.